J&J’s Darzalex Scores Again In Frontline Myeloma

But Challenger Arriving In 2020

 
• By Andrew McConaghie
  
Johnson_and_Johnson
CAR-T candidate JNJ-4528 is set to add to Darzalex and Imbruvica in J&J's hemato-oncology franchise
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip